Mixed cytomegalovirus (CMV) infections are associated with delayed viral clearance in solid organ transplant recipients. We investigated whether this could be extrapolated to allogeneic stem cell transplant (allo-SCT) recipients. A total of 48 plasma specimens, obtained during 29 episodes of active CMV infection in 25 non-consecutive allo-SCT patients, were analysed. Baseline blood specimens, drawn shortly prior to the inception of pre-emptive antiviral therapy (pre-treatment specimen; n=29), as well as follow-up samples obtained either after the initiation of antiviral therapy (post-treatment specimen; n=15) or during recurrent episodes (n=4) were analysed. Plasma CMV DNA loads were quantified by real-time PCR and the CMV genotyping was performed by ultra-deep sequencing of hypervariable regions in the genes coding for glycoproteins N (gN) and O (gO). A trend towards higher CMV DNA peak loads, longer CMV DNAemia episode durations and slower CMV DNAemia decay rates was observed for episodes with mixed CMV genotype populations compared to those caused by single CMV variants, although the differences did not reach statistical significance. The length of the treatment course required to clear DNAemia was significantly longer in these mixed episodes (P=0.002). Significant changes in the number or frequency of CMV gN or gO genetic variants were documented following the initiation of antiviral therapy or in recurrent episodes. CMV diversity may have a major impact on the kinetics of CMV DNAemia clearance during the treatment of active CMV infection episodes in allo-SCT recipients.
INTRODUCTION
Cytomegalovirus (CMV) is a large double-stranded DNA virus with a genome size of about 235 Kb [1] that exhibits a high degree of variability, particularly in genes encoding envelope glycoproteins, such as gB (UL55), gO (UL74), gN (UL73) and UL139, and viral evasion genes, including UL144, UL146 and UL147 (reviewed in [2, 3] ). Recent data have provided evidence that CMV may exist as a complex mixture of genome types in humans [4] , most strikingly in CMV-seropositive transplant patients who are reinfected by donor-derived CMV strains [5] . CMV infection remains a frequent cause of morbidity in allogeneic stem cell transplant (allo-SCT) recipients, despite major advancements in CMV surveillance methods and the availability of antivirals with relatively high intrinsic activity against the virus [6] .
Allo-SCT patients who develop viraemia are most commonly managed by a pre-emptive antiviral therapy approach [6, 7] in which antiviral treatment is initiated upon the detection of CMV DNA blood loads above a predetermined threshold, although this limit varies widely across institutions [8] . Both the in vivo susceptibility of CMV to antivirals and, notably, the magnitude of the CMV-specific functional CD8 + and CD4 + T cell expansion triggered by CMV replication are known to exert a major force on the dynamics of viraemia in these patients [9, 10] . Nevertheless, data obtained in the solid organ transplantation (SOT) setting suggest that CMV genetic complexity may also be relevant, because mixed CMV infections appear to be associated with higher viral loads, delayed viral clearance and poorer clinical outcomes [11] [12] [13] . Whether these observations can be extrapolated to the allo-SCT setting is yet to be elucidated. Here, we aimed to determine the genetic diversity of the viral population present during episodes of active CMV infection in allo-SCT recipients by means of ultra-deep sequencing of hypervariable regions in the genes coding for glycoproteins N (gN) and O (gO), and to assess whether this parameter influences the dynamics of CMV DNAemia clearance following the inception of antiviral treatment.
RESULTS
Cytomegalovirus population genetic diversity in cytomegalovirus DNAemia episodes in allo-SCT recipients First, we determined the CMV population's genetic diversity in blood samples drawn during episodes of active CMV infection before the initiation of pre-emptive antiviral therapy. CMV genotyping was performed by ultra-deep sequencing (UDS) of hypervariable regions in the genes coding for gN and gO. We analysed 34 pre-treatment plasma specimens, each from separate CMV DNAemia episodes that occurred in 30 different patients. We were unable to amplify CMV DNA suitable for UDS from five of these specimens. We could not identify any differential features for these failed samples (data not shown). Thus, we finally included pre-treatment plasma specimens from 29 CMV DNAemia episodes in 25 patients (Table 1) ; 21 of these were the first episode and developed at a median of 33 days (range 4-66 days) after transplant, while 8 were recurrent episodes that occurred at a median of 140.5 days (range 101-368 days) after transplant. The relevant features of the episodes are shown in Table 2 . Of note, all but five episodes (occurring in patients who eventually died) resolved after the administration of antiviral treatment. The performance of genotypic drug resistance tests in these five cases was deemed to be unnecessary because the patients died within 3 weeks after the initiation of pre-emptive therapy. At our institution, resistance tests are conducted upon the detection of significant CMV DNA load increases after 3 weeks of antiviral treatment.
UDS yielded between 657 612 and 12 530 sequences per sample and amplicon set (average 93 904 sequences). The length of the gN and gO CMV genetic variants ranged from 349 to 361 nucleotides and 246 to 255 nucleotides, respectively. Minimum sequence depths were 571 sequences for the less represented gN genetic variant (nP12pre sample, 0.009 %) and 1188 sequences for the less represented gO gene genetic variant (oP18post sample, 0.012 %; Tables S1 and S2, available in the online Supplementary Material), respectively. Globally, 15 gN protein genetic variants were found for UL73: three genotype 1 (GT1), two genotype 2 (GT2), two genotype 3 (GT3) and eight genotype 4 (GT4); six matched reference sequences, seven were identical to GenBank sequences and two were new sequences (both only differed from the nearest deposited sequences by a single nucleotide). Interestingly, patient 28 exhibited a mixed population of two gN variants with a difference in only one UL73 codon. Similarly, 13 genetic variants were detected for UL74 encoding gO genetic variants: 5 GT1, 4 GT2, 2 GT3 and 2 GT5; 10 matched reference sequences, 4 were identical to deposited sequences and 1 was a new sequence (only differing from the most similar deposited sequence by a single nucleotide). Phylogenetic trees for the CMV gN and gO genetic sequences are shown in Fig. 1. A single gN or gO genetic variant was found in 11 pre-treatment specimens, while the remaining 18 specimens contained more than 1 variant. Specifically, when the UL73 sequences were analysed, 13 specimens contained 2 variants, 4 contained 3 variants and 1 specimen had 4 variants; UL74 sequence analyses yielded 11, 6 and 1 specimen(s) containing 2, 3, or 4 variants, respectively (Fig. 2, Tables 3, S2 and S3 ).
Cytomegalovirus population genetic diversity and dynamics of cytomegalovirus DNAemia clearance Next, we investigated whether CMV genetic diversity prior to the administration of antiviral therapy had any impact on the kinetics and duration of CMV DNAemia (Table 4) . A trend towards higher CMV DNA peak loads, longer CMV DNAemia episode durations and slower decay rates (halflives) were observed for episodes involving more than one genetic variant (gN, gO, or both), but these differences did not reach statistical significance. Nevertheless, the duration of antiviral treatment courses required to achieve CMV DNAemia clearance was significantly longer in genetically mixed CMV episodes compared to episodes involving only one genetic variant, regardless of whether UL73 or UL74 sequences were considered for the analyses. This effect was independent of the criteria established to interrupt antiviral therapy (see the Methods section), or the antiviral agent used (usually valganciclovir; data not shown). In this context, it is of relevance to underline the fact that mixed genotypes were seen in two out of the five episodes that were active at the time of a patient's death. Likewise, the combined gN and gO haplotype correlated significantly with the nucleotide diversity indexes and the length of antiviral treatment courses (Table 5 ).
We must stress that neither the demographics nor the pre-/ post-transplant clinical characteristics differed significantly between patients with genetically mixed or single-variant CMV infections (Table S3 ). In particular, the use of high doses of corticosteroids to treat acute graft-versus-host disease (aGvHD; grades II-IV) -which significantly impair CMVspecific functional T cell expansion [9] -was comparable in both groups. In addition, both the initial CMV DNA load and the nature of the episode (initial vs recurrent) were also similar between the two groups (P>0.5). Furthermore, undetectable levels of CMV-specific polyfunctional (bifunctional +trifunc-ctional) CD8 + T cells were observed in most episodes (in 11 out of 13 episodes from which immunological data were available -5 with a mixed CMV population and 6 with a single variant) prior to the initiation of antiviral therapy (median, 19 days; range, 7-30 days). This is relevant because the level of peripheral CMV-specific functional CD8 + T cells present, either prior to or at the time of CMV DNAemia onset, influences the kinetics of CMV DNAemia clearance in allo-SCT recipients dramatically [9, 10] .
Dynamics of cytomegalovirus genetic variants following the initiation of antiviral treatment
We then investigated whether antiviral therapy administration affected the number or frequency of CMV gN or gO genetic variants. Post-treatment plasma specimens, obtained at a median of 14 days (range, 4-52 days) after antiviral therapy initiation, were available for 15 out of the 29 CMV DNAemia episodes (Fig. 2, Tables 3, S1 and S2). The analysis of these samples revealed a significant difference in either the number or frequency of variants in the pre-and posttreatment paired samples in nearly half the cases (7 of 15 for gN; Table S4 ). However, the results differed slightly, depending on the genome region used for the comparison: gN analyses yielded a better resolution (two more cases with significant differences) than for gO. In most cases, there was a decrease in genetic complexity (fewer variants or lower frequencies of one or more variants) over time, and the appearance of new genetic variants after antiviral treatment inception was not observed. Interestingly, the nucleotide sequences of the individual UL73 or UL74 variants remained stable over time.
Following this, we investigated whether changes in the genetic composition of the gN/gO protein populations present during antiviral treatment had any impact on the length of antiviral treatment courses. We found that the number of treatment days required to clear CMV viraemia was comparable, irrespective of whether or not there were any changes in the CMV population (P=0.463 and P=0.090 for UL73 and UL74, respectively).
Variation in cytomegalovirus genetic populations in recurrent episodes of cytomegalovirus DNAemia Finally, we investigated whether variations in the number or frequency of genetic variants occurred during recurrent AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; BM, bone marrow; CLL, chronic lymphoid leukaemia; CML, chronic myeloid leukaemia; D, donor; GvHD, graft-versus-host disease; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; PB, peripheral blood; R, recipient. *HLA-mismatch was defined as the presence of one disparity in 10 HLAs at A, B, C, or DRB1 loci, as determined by high-resolution genotyping in either sibling or unrelated donors. †AGvHD was diagnosed and graded (grades II-IV are severe), as previously reported in Glucksberg et al. [37] .
episodes of CMV DNAemia. Four patients in our cohort (patients 1, 15, 16 and 22) developed a recurrent episode. The time elapsed between the initial and the relapse episodes was 77, 109, 84 and 66 days, respectively. Significant variations in the number or frequency of CMV gN or gO genetic variants were observed in three of the episodes (Table S5) . A reduction in the complexity of these genetic populations was seen in all cases, and no new variants emerged compared to those found in the initial episodes.
DISCUSSION
Genetic heterogeneity in CMV was first reported some time ago [14] and now recent studies have exhaustively characterized it through full-genome analyses using UDS methods [15] [16] [17] . It is biologically feasible that a correlation between viral genetic variability and strain pathogenicity exists [2] , yet definitive evidence supporting this is lacking. An increasing body of experimental evidence suggests that mixed-genotype infections in SOT patients may be associated with delayed clearance of viraemic episodes and worse clinical outcomes [11] [12] [13] . In the Allo-SCT setting, two recent studies failed to prove an association between infections with mixed gB (UL55 gene) genotypes and a higher incidence of CMV end-organ disease [18, 19] . They genotyped UL55 either by PCR-restriction fragment-length polymorphism analysis [18] or by nested PCR [19] , and thus it was not possible to achieve a precise estimation of the genetic complexity of the viral population. Given the demonstrated utility of UL73 and UL74 UDS for assessing viral population diversity in SOT recipients [5, 20] , here we employed the same technique in highly polymorphic regions of these same genes to investigate the impact of gN and gO genetic diversity in the CMV population on the dynamics of CMV DNAemia clearance. oP12pre  oP12post  oP32pre  oP01E1pre  oP05pre  oP05post  oP19pre  oP19post  oP23pre  oP23post  gO GT1b SW990  oP02pre  oP02post  oP03pre  oP03post  oP10pre  oP11pre  oP11post  oP18pre  oP18post  oP20post  oP21pre  oP22E1pre  oP22E1post  gO GT3 SW5  oP03pre  oP03post  oP16E1pre  oP16E2pre  oP17pre  oP17post  oP06pre  oP06post  oP12pre  oP14pre  oP18pre  oP18pre  gO GT3 1960  oP21pre  oP01E1pre  oP01E2pre  oP04pre  oP04post  gO GT5 Merlin  oP10pre  oP22E1pre  oP22E2pre gO GT4 Towne We drew several conclusions from our data. First, mixed infections are common in allo-SCT recipients, irrespective of their pre-transplantation or donor CMV serostatus. This concurs with previous observations in allo-SCT and SOT settings [5, [11] [12] [13] [18] [19] [20] [21] . Second, while the initial plasma CMV DNA loads were comparable in both multiple-and single-genetic-variant episodes, the peak CMV DNA load and CMV DNAemia episode duration tended to be higher in multiple-variant viraemia. Furthermore, the rate of CMV DNAemia decay in plasma, as inferred from the CMV DNA half-lives, was slower in episodes with greater CMV population genetic diversity, and most notably, the duration of antiviral treatment until viraemia clearance was significantly longer in these episodes than in those involving only one genetic variant. This effect was apparently independent of pre-transplant and post-transplant clinical factors, the therapeutic regimen used, the criterion for stopping antiviral treatment and the nature of the episode (initial vs recurrent), thus suggesting that viral-population genetic diversity may indeed be an independent marker of delayed viral clearance. 
P 0 1 E 2 P 0 2 p re P 0 2 p o st P 0 3 p re P 0 3 p o st P 0 4 p re P 0 4 p o st P 0 5 p re P 0 5 p o st P 0 6 p re P 0 7 p re P 0 6 p o st P 0 8 p re P 0 8 p o st P 0 9 p re P 0 9 p o st P 1 1 p re P 1 1 p o st P 1 2 p re P 1 5 E 1 p re P 1 6 E 1 p re P 1 6 E 2 p re P 2 2 E 1 p re P 2 2 E 2 p re P 1 5 E 2 p re P 1 2 p o st P 1 7 p re P 1 7 p o st P 1 8 p re P 1 8 p o st P 1 9 p re P 1 9 p o st P 2 0 p re P 2 0 p o st P 2 3 p re P 2 3 p o st P 2 4 p re P 2 8 p re P 3 2 p re P 2 4 p o st P 2 1 p re P 1 4 p re P 1 0 p re Unfortunately, the low number of episodes included in this study precluded the performance of any meaningful multivariable analyses. However, in support of this hypothesis, the polyfunctional CMV pp65/IE-1-specific CD8 + T cell response, analysed shortly after the onset of CMV DNAemia (and prior to the initiation of antiviral therapy) was comparable between single and mixed CMV genotype variant episodes. In fact, undetectable responses were observed in most episodes. This is relevant because the duration of CMV DNAemia episodes is inversely related to the number of polyfunctional CD8 + T cells present prior to (or at the time of) CMV DNAemia detection [22, 23] . Nevertheless, these data should be interpreted with caution, as we did not monitor the dynamics of CMV-specific T-cell expansion over time, and nor did we determine the epitope-specificity of the expanding T-cell populations.
In this context, recent observations seem to indicate that the induction of a stable CMV-specific T-cell response against either conserved or cross-reactive IE-1-epitopes, rather than CMV genetic diversity itself, is associated with efficient CMV viraemia control in allo-SCT recipients [21] . Although they are speculative, there are several potential, non-mutually exclusive, explanations for our findings.
First, mixed CMV viral infections are more likely to feature variants with decreased susceptibility to antiviral treatment than those with a single CMV genetic variant. Nevertheless, gN and gO genes do not appear to be in linkage disequilibrium with UL97 (encoding a viral kinase that phosphorylates ganciclovir) or UL54 (encoding a viral polymerase) [16] . Neither phenotypic nor genotypic susceptibility/resistance assays were performed to investigate this possibility, which certainly can be considered to be a limitation of this study. Although it is speculative, in our view, the lack of a robust expansion of functional CMV-specific T cells upon CMV replication rather than the emergence of variants with decreased susceptibility to antivirals was the main driving force accounting for the occurrence of long-lasting episodes of CMV DNAemia (the plasma CMV DNA load fluctuated rather than increasing significantly over time) [22, 23] .
Second, mixed infections may pose a greater challenge to the immune system than single infections, especially when recipient and donor-derived variants coexist, as previously suggested [13] . However, we cannot definitively rule out the reverse hypothesis, that mixed-genotype infections mostly arise in patients with poor CMV-specific immunity, although our data do not seem to support this idea.
Third, qualitative changes in viral fitness, leading to enhanced pathogenicity, may occur in multiply-infected hosts as a result of functional trans-complementation within coinfected cells [24] or intrahost recombination [15] , although the methodology used in this work does not allow its documentation.
Fourth, the number or relative frequency of CMV genetic variants changed after the inception of antiviral treatment in nearly half the cases we analysed. This observation most likely reflects differences in the individual susceptibility of the gN/gO genetic variants to antiviral agents, T cell-mediated immune responses, or both, although other explanations (e.g. stochasticity or promotion by proinflammatory or stress signals) cannot be ruled out completely. Nevertheless, changes in the CMV genotype diversity did not appear to impact on the length of the antiviral courses required to achieve CMV DNAemia clearance. Similar changes were observed in recurrent CMV DNAemia episodes, but no new genetic variants were documented, suggesting that the spectrum of CMV variants in a given patient may remain stable over time.
Fifth, no new mutations in the CMV gN/gO variant nucleotide sequences were detected after antiviral therapy administration or during recurrent episodes. This could be attributed to a very low mutation rate (estimated in the 1Á10 À8 to 1Á10 À9 range by computation of the maximum mutation rate that would give a probability of 0.05 or lower of observing no new mutations in the two CMV genes analysed), to the action of strong selection on these genes, or to both factors. In any case, this indicates that within-patient CMV populations are more stable than previously postulated with a whole-genome sequencing approach [15] . In this sense, we adopted a rather conservative approach for the estimation of within-host genotypic diversity, so that only previously described (and deposited) variants were retained for the analyses. It is unclear whether such a stringent approach was employed in previous studies claiming the existence of high within-patient genotypic variability over time [15] . This apparent discrepancy will only be settled when more evidence accumulates. Statistically significant associations are shown in bold. *Differences between medians were compared using the Mann-Whitney U test. Two-sided exact P-values are reported. A P-value <0.05 was considered to be statistically significant.
In addition to the above-mentioned omission of resistance tests, the current study has some limitations that may have led to the underestimation of the number of multiple strain infections. First, it is possible that minor strains are less easily detected in samples with lower DNA loads than in those with higher ones. Second, we analysed two closely linked regions of the CMV genome and it is possible that in these samples they are not fully representative of the genetic variability at the whole-genome level. Third, CMV DNA in plasma is almost exclusively free DNA, highly fragmented, and not virion-associated, so that not all virus diversity might be captured [25] . Additionally, we analysed a limited number of episodes.
In summary, our data indicate that genetic diversity in the CMV population may influence the kinetics of CMV DNAemia clearance in allo-SCT recipients, thus determining the length of antiviral treatment needed for viraemia clearance. Although it is speculative, one could envision viral diversity analysis, perhaps by whole-genomic sequencing directly from clinical specimens [15] [16] [17] , as an ancillary tool for estimating the risk of prolonged CMV viraemia in allo-SCT patients, therefore helping to optimize and individualize pre-emptive antiviral treatments. In our opinion, given the potential clinical relevance of our findings, further studies with larger cohorts are warranted in order to further explore these possibilities.
METHODS
Patients and samples A total of 53 plasma specimens, obtained during 34 episodes of active CMV infection in 30 non-consecutive allo-SCT patients, were included in this retrospective study. The patients underwent allo-SCT in the Hematology Unit at the Hospital Clínico Universitario in Valencia, Spain between May 2013 and December 2014. We analysed baseline blood specimens, drawn shortly prior to the inception of pre-emptive antiviral therapy (pre-treatment specimen; n=34), as well as follow-up samples obtained either after the initiation of antiviral therapy (post-treatment specimen; n=15) or within recurrent episodes (n=4). A minimum volume of 1 ml was required for the studies described below. The availability of a sufficient volume of plasma was the only restrictive criterion for the inclusion of cases. The plasma samples were retrieved from storage at À80 C for the analyses and had never been previously thawed.
Virological monitoring and active cytomegalovirus infection management
Pre-emptive antiviral therapy with valganciclovir, i.v. ganciclovir or foscarnet was initiated upon the detection of >1000 copies ml À1 (1500 IU ml
À1
) of CMV DNA in plasma, as determined by quantitative real-time PCR (Abbott RealTime CMV assay; Abbott Molecular, Des Plaines, IL, USA; detection limit, 20 copies ml À1 or 31.5 IU ml
) and was interrupted upon the documentation of two consecutive negative (undetectable) PCR results after a minimum of 2 weeks' treatment (until January 2014) or at the first negative PCR result (after April 2014), as previously described [10, 26] . The virological load was monitored at least once a week during active CMV infection episodes.
PCR amplification for Illumina sequencing
Total DNA was isolated from 1 ml of plasma using the NucliSENS easyMAG extraction platform (bioM erieux, L'Etoile, France) with a 35 µl elution volume. Each viral DNA isolation round (maximum 23 samples) included a negative extraction control consisting of PCR-grade water that was subsequently used in PCR amplification. Two CMV regions of about 361 and 255 bp in UL73 and UL74 (gN and gO proteins, respectively) were amplified in an initial PCR [5] , followed by a hemi-nested PCR using oligonucleotides extended at the 5¢ end with Illumina adapters (Table S6 ). The PCR reactions were carried out with the KAPA HiFi HotStart DNA 2Â ready mix (KAPA Biosystems) with either 4.4 µl of eluted DNA (first PCR) or 1 µl of the first PCR product (hemi-nested PCR) under the following conditions: 95 C for 3 min; 25 cycles of 98 C for 20 s, Sequence analysis and genotype frequency estimates Quality assessment of the generated pair-end reads, R1 and R2, was performed using the 'prinseq-lite' program [27] applying 3¢ trimming to maintain at least a mean quality score of 20 in 20 bp windows. Generated pair reads were joined with the 'fastq-join' command-line program implemented in the ea-tools suite [28] . Alignments were built with the InDel Fixer program (https://github.com/cbg-ethz/ InDelFixer) using the gN or gO genotypes described in Görzer et al. [5] as reference sequences. The QuasiRecomb program [29] was then used to obtain reconstructed DNA sequences and their relative frequencies within samples. Finally, in order to remove chimaeric sequences synthesized either in the PCRs or in the joining of pair-end reads, we implemented the UCHIME algorithm [30] in the USEARCH software package using the same reference sequences as above. Underrepresented sequences, with frequencies below 10 À4 , were removed from the analysis.
Genetic and phylogenetic analyses
The haplotype diversity index (Hap) and the nucleotide diversity index (Pi) were obtained using the DnaSP program, version 5 [31] . Combined measures of diversity for the two genome regions were obtained as weighted averages of the corresponding estimates. The genetic composition of CMV populations in pre-and post-treatment samples from the same individual were compared using the randomization test implemented in the Arlequin program, version 3.5.2.2 [32] . Sequence alignments for each sample with reference sequences were performed with CLUSTALW 2.1 [33] . Maximum-likelihood phylogenetic trees were built with RAxML, version 8.2.8 [34] , with the general time-reversible model of nucleotide substitution, a gamma-distribution approximation to account for rate-heterogeneity and bootstrap support for branches through the use of 1000 replicates. The trees were edited using the Tree Explorer tool in MEGA5 [35] . Finally, the GenBank accession numbers for the sequences derived in this study are LT622645 to LT622799.
Immunological monitoring
Polyfunctional CMV-specific (IE-1+pp65) CD8 + T cells were enumerated by intracellular cytokine staining (ICS), as previously described [22, 23] . We specifically quantified bifunctional (either producing IFN-g+TNF-a, or producing and expressing IFN-g+CD107 a and TNF-a+CD107 a) and trifunctional (IFN-g/TNF-a/CD107a) CMV-specific CD8 + T cells.
Cytomegalovirus DNAemia dynamics
The plasma CMV DNA-load half-life was calculated following the formula N t =N 0 e-lt, where N 0 is the initial CMV DNA load, N t is the viral load remaining after a time t, t 1/2 is the half-life and l is the decay constant. It follows that t 1/2 =ln(2)/l [36] .
Definitions
A recurrent episode of CMV DNAemia was one that occurred at least 15 days after resolution of the previous one. The duration of CMV DNAemia was the period of time between the day of the first positive PCR result and the day of the first negative PCR result. For episodes that had not been cleared at the time of the patient's death, the day of the last positive PCR result was considered for the analyses.
Statistical analyses
The frequency of genetic variants was compared using the 2 test (Fisher exact test). Differences between medians were compared using the Mann-Whitney U test (two independent variables). Two-sided exact P-values are reported; a P-value <0.05 was considered to be statistically significant. Data were analysed with the aid of the statistical package SPSS, version 20.0 (SPSS). The association between virological variables and Hap and Pi indices was tested using Spearman rho tests via the R package (http://www.R-project.org/). 
